| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Bruce Wendel is Director at GTBP. Bruce Wendel's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $1.9M at current prices.
Net of sales, the GTBP filings show accumulation of 5,083 shares.
Bruce Wendel has 10 Form 4 filings on record from June 2016 to October 2026, across 4 companies: Director at PDS Biotechnology (PDSB), 2026; Director at ImmunityBio (IBRX), 2025–2026; Director at GT Biopharma (GTBP), 2020–2023, and 1 more.
The 15 reported transactions were 11 option or other derivative awards, 3 open-market purchases and 1 stock award.
Counted by filing, the open-market trades come to 1 purchase worth about $26K and no sales.
The only open-market purchase was 5,083 shares of GTBP at an average $5.17 on December 22, 2020, about $26K.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Dec 22, 2020 | GTBP Gt Biopharma, Inc. | Director | Buy | 5,083 | $5.17 | $26,298.83 | New |